These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30834671)

  • 1. Applying the Hippocratic Oath in breast cancer-The case for promoting prevention.
    Anampa JD; McEvoy MP; Feldman S; Sparano JA
    Breast J; 2019 Mar; 25(2):187-189. PubMed ID: 30834671
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
    Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
    J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative management of breast cancer in BRCA1/2 mutation carriers.
    Alpert TE; Haffty BG
    Clin Breast Cancer; 2004 Apr; 5(1):37-42. PubMed ID: 15140283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
    Marchetti P; Di Rocco CZ; Ricevuto E; Bisegna R; Cianci G; Calista F; Sidoni T; Porzio G; Ficorella C
    Ann Oncol; 2004; 15 Suppl 1():I27-I34. PubMed ID: 15280184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of hereditary breast cancer].
    Taguchi T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():610-4. PubMed ID: 17682218
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
    Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
    J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
    Eeles RA; Powles TJ
    J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen for the prevention of breast cancer in high-risk women.
    Sweeney FW; Newton WP
    J Fam Pract; 1999 Feb; 48(2):90-1. PubMed ID: 10037532
    [No Abstract]   [Full Text] [Related]  

  • 10. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
    Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
    Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
    Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer prevention in high-risk women: searching for new options.
    Nelson NJ
    J Natl Cancer Inst; 2011 May; 103(9):710-1. PubMed ID: 21515834
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk-reducing mastectomy for BRCA gene mutation carriers.
    Euhus DM
    Ann Surg Oncol; 2015 Sep; 22(9):2807-9. PubMed ID: 25821000
    [No Abstract]   [Full Text] [Related]  

  • 15. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen's effect in women with breast cancer.
    Eisinger F; Julian-Reynier C; Sobol H
    Lancet; 2001 Apr; 357(9264):1291-2. PubMed ID: 11421212
    [No Abstract]   [Full Text] [Related]  

  • 17. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    Levy-Lahad E; Lahad A; King MC
    J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
    [No Abstract]   [Full Text] [Related]  

  • 18. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
    Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
    Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary.
    Fisher B
    J Clin Oncol; 1999 May; 17(5):1632-9. PubMed ID: 10334553
    [No Abstract]   [Full Text] [Related]  

  • 20. [Tamoxifen in prophylaxis of breast cancer].
    Bogush TA; Bogush EA
    Antibiot Khimioter; 2001; 46(1):30-4. PubMed ID: 11221083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.